Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Bram C. Agema"'
Autor:
Bram C. Agema, Sanne M. Buijs, Sebastiaan D.T. Sassen, Thomas E. Mürdter, Mathias Schwab, Birgit C.P. Koch, Agnes Jager, Ron H.N. van Schaik, Ron H.J. Mathijssen, Stijn L.W. Koolen
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 160, Iss , Pp 114369- (2023)
Background: Tamoxifen is important in the adjuvant treatment of breast cancer. A plasma concentration of the active metabolite endoxifen of > 16 nM is associated with a lower risk of breast cancer-recurrence. Since inter-individual variability is hig
Externí odkaz:
https://doaj.org/article/2396b06ab4c94959a7fe50d0e9284b90
Autor:
Bram C. Agema, G. D. Marijn Veerman, Christi M. J. Steendam, Daan A. C. Lanser, Tim Preijers, Cor van der Leest, Birgit C. P. Koch, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Stijn L. W. Koolen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Osimertinib is the cornerstone in the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC). Nonetheless, ±25% of patients experience severe treatment-related toxicities. Currently, it is impossible to
Externí odkaz:
https://doaj.org/article/0954342ab709469f8e0750b0bc63082a
Autor:
Bodine P. S. Belderbos, Mirjam de With, Rajbir K. Singh, Bram C. Agema, Samira El Bouazzaoui, Esther Oomen-de Hoop, Ronald de Wit, Ron H. N. van Schaik, Ron H. J. Mathijssen, Sander Bins
Publikováno v:
Cancer Chemotherapy & Pharmacology, 85(3), 547-553. Springer-Verlag
Purpose: Cabazitaxel, used in patients with metastatic castration-resistant prostate cancer (mCRPC), is associated with adverse events which may require dose reductions or discontinuation of treatment. We investigated the potential association of sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47ff41a3c6b9dc529cd92610958b089d
https://doi.org/10.1007/s00280-019-04011-0
https://doi.org/10.1007/s00280-019-04011-0
Autor:
Ron H.J. Mathijssen, Carin C.D. van der Rijt, Sebastiaan D.T. Sassen, Birgit C. P. Koch, Bram C. Agema, Astrid W. Oosten, Stijn L.W. Koolen, Wim J R Rietdijk
Publikováno v:
Cancers, Vol 13, Iss 2768, p 2768 (2021)
Cancers
Volume 13
Issue 11
Cancers, 13(11):2768. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Volume 13
Issue 11
Cancers, 13(11):2768. Multidisciplinary Digital Publishing Institute (MDPI)
Oxycodone is frequently used for treating cancer-related pain, while not much is known about the factors that influence treatment outcomes in these patients. We aim to unravel these factors by developing a population-pharmacokinetic model to assess t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01538e78b3c04ce9eba8ddfe28041d52
https://www.mdpi.com/2072-6694/13/11/2768
https://www.mdpi.com/2072-6694/13/11/2768
Autor:
Andrew KL Goey, Mirjam de With, Bram C Agema, Esther Oomen-De Hoop, Rajbir K Singh, Astrid AM van der Veldt, Ron HJ Mathijssen, Ron HN van Schaik, Sander Bins
Publikováno v:
Pharmacogenomics, 20(18), 1283-1290. Future Medicine Ltd.
Aim: The pharmacokinetics and pharmacodynamics of vemurafenib are characterized by a wide interpatient variability. Since multiple polymorphic enzymes and drug transporters are involved in vemurafenib pharmacokinetics, we studied associations of poly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9206022b2fa670fc3d7d992283198849
https://pure.eur.nl/en/publications/f05ea6a0-f9e8-4c7e-9e47-b326a75dea21
https://pure.eur.nl/en/publications/f05ea6a0-f9e8-4c7e-9e47-b326a75dea21
Autor:
Bram C. Agema, Stijn L.W. Koolen, Mirjam de With, Nadia van Doorn, Niels Heersche, Esther Oomen-de Hoop, Sabine Visser, Joachim G.J.V. Aerts, Sander Bins, Ron H.N. van Schaik, Ron H.J. Mathijssen
Publikováno v:
Genes
Volume 11
Issue 4
Genes, 11(4):358. Multidisciplinary Digital Publishing Institute (MDPI)
Genes, Vol 11, Iss 358, p 358 (2020)
Volume 11
Issue 4
Genes, 11(4):358. Multidisciplinary Digital Publishing Institute (MDPI)
Genes, Vol 11, Iss 358, p 358 (2020)
Cisplatin is a chemotherapeutic agent widely used for multiple indications. Unfortunately, in a substantial set of patients treated with cisplatin, dose-limiting acute kidney injury (AKI) occurs. Here, we assessed the association of 3 catechol-O-meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::617de176c0ee01ee4c2492400a6f21d4
Autor:
Bodine P S, Belderbos, Mirjam, de With, Rajbir K, Singh, Bram C, Agema, Samira, El Bouazzaoui, Esther, Oomen-de Hoop, Ronald, de Wit, Ron H N, van Schaik, Ron H J, Mathijssen, Sander, Bins
Publikováno v:
Cancer chemotherapy and pharmacology. 85(3)
Cabazitaxel, used in patients with metastatic castration-resistant prostate cancer (mCRPC), is associated with adverse events which may require dose reductions or discontinuation of treatment. We investigated the potential association of single-nucle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::449bddcf8f161fbde0c251766b32c2ea
https://pubmed.ncbi.nlm.nih.gov/31893292
https://pubmed.ncbi.nlm.nih.gov/31893292
Autor:
Bram C. Agema, Sanne M. Buijs, Sebastiaan D.T. Sassen, Thomas E. Mürdter, Matthias Schwab, Birgit C.P. Koch, Agnes Jager, Ron H.N. van Schaik, Ron H.J. Mathijssen, Stijn L.W. Koolen
Publikováno v:
Biomedicine and Pharmacotherapy, 160:114369. Elsevier Masson
BACKGROUND: Tamoxifen is important in the adjuvant treatment of breast cancer. A plasma concentration of the active metabolite endoxifen of > 16 nM is associated with a lower risk of breast cancer-recurrence. Since inter-individual variability is hig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1a567ea127e3d9b50d5d65bfad83951
https://pure.eur.nl/en/publications/9012b2b0-9bf9-413a-8686-34126b61f7e6
https://pure.eur.nl/en/publications/9012b2b0-9bf9-413a-8686-34126b61f7e6
